Hyperbaric Oxygen Therapy - Hyperbaric Chamber Information ...
Hyperbaric Oxygen Therapy - Hyperbaric Chamber Information ...
Hyperbaric Oxygen Therapy - Hyperbaric Chamber Information ...
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
Conclusions<br />
Safety<br />
Potential risks for patients undergoing therapy with hyperbaric oxygen are myopia,<br />
barotrauma, claustrophobia or oxygen toxicity. Estimates of incidence are uncertain,<br />
although most adverse events are self-limiting and resolve after termination of therapy.<br />
Serious, life-threatening events are rare, but real, causes of major concern.<br />
Published guidelines seek to provide industry-wide acceptance of recommendations and<br />
requirements for the safe operation of hyperbaric facilities. Staffing levels, training, and<br />
qualifications are explicitly provided by these documents.<br />
Effectiveness<br />
The evaluation found evidence of HBOT effectiveness in diabetic wounds and limited<br />
evidence of effectiveness in the prevention of osteoradionecrosis, crush injuries, cluster<br />
and migraine headaches and facial paralysis. Insufficient evidence or conflicting evidence<br />
for HBOT use was found in the following conditions: thermal burns, non-diabetic<br />
wounds, necrotising soft tissue infections, treatment of osteoradionecrosis, skin graft<br />
survival, cerebrovascular disease, peripheral obstructive arterial disease, sudden deafness,<br />
cancer of the head and neck, cervix and bladder, lymphoma and neuroblastoma, carbon<br />
monoxide poisoning, necrotising arachnidism, actinomycosis, soft tissue radionecrosis,<br />
cerebral palsy, Crohn’s disease, Legg-Calve-Perthes disease and osteoporosis.<br />
There is evidence of a lack of any beneficial effect in multiple sclerosis and limited<br />
evidence of a lack of effectiveness in osteomyelitis, acute myocardial infarction, acute<br />
ankle sprains and cancer of the lung.<br />
The following indications were not formally evaluated as the Supporting Committee<br />
agreed that they have little clinical acceptance and/or have been minimally reported in<br />
the literature: cyanide poisoning, head trauma, cerebral oedema, acquired brain injury,<br />
cognitive impairment, senile dementia, glaucoma, keratoendotheliosis, HIV infection,<br />
anaemia from exceptional blood loss, insulin dependent diabetes mellitus, facial neuritis,<br />
arthritis, spinal injuries and non-union of fractures.<br />
Cost-effectiveness<br />
The estimated cost of monoplace HBOT treatment in this report is not a precise estimate<br />
based on actual studies, but is based on estimates of staffing and capital costs of a<br />
hyperbaric monoplace unit from expert opinion. Moreover the evidence of effectiveness<br />
used is subject to considerable uncertainty as detailed in the clinical effectiveness sections<br />
of the report. This means that the cost-effectiveness ratios presented here are only<br />
indicative estimates, which may be sensitive to more precise estimates of the costs and<br />
effectiveness of HBOT treatment. Based on this evidence it seems that HBOT could be<br />
cost-effective in the treatment of diabetic wounds, and necrotising soft tissue infections.<br />
It could save resources in those treatments. The cost of $28,480 per case of<br />
<strong>Hyperbaric</strong> oxygen therapy 91